Understanding the Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19: Findings From a Systematic Review

Sarah Abdullah Aldukhi, Mohammed Batais

Abstract


Background: Inhibitors of dipeptidyl peptidase-4 (DPP4) have been used for diabetic patients and there is debate around using the same DPP4 inhibitors as a potential source of treatment for severe coronavirus disease 2019 (COVID-19). The findings from individual studies regarding the usage of DDP4 inhibitors on COVID infection are available but not reviewed and synthesized. Therefore, we aimed to conduct a systematic review to synthesize the findings regarding its effect on the COVID infection course and the outcome.

Methods: We carried out an electronic search in Google Scholar and PubMed. We considered a study eligible if it was an original research study, published in English during the era of COVID-19 till September 2021, and had provided information on the topic of DPP4 inhibitors and COVID infection followed by reviewing the full-text articles and summarizing their findings.

Results: This review provided novel insights into the effect of DDP4 inhibitor users and its effect on COVID-19 patients. Overall, literature is scarce on the effect of DDP4 inhibitors on COVID severity and we found mixed results regarding the DDP4 effects on disease severity and mortality. The evidence is not consistent currently as some of the studies supported the role of DDP4 inhibitor, while other studies provided contradictory findings. UK population data published in 2021 with 2.5 million diabetic patients found no evidence to support a protective effect of DDP inhibitors on morbidity and mortality related to COVID-19.

Conclusion: The findings of the review reveal that there is some benefit of the usage of DDP4 inhibitors on COVID-19 morbidity and mortality. However, we highly recommend replicating the studies in different contexts before making any strong recommendations. Furthermore, the results need to be interpreted cautiously due to the scarcity of literature on the role of DDP4 inhibitors among diabetic patients with COVID-19.




J Endocrinol Metab. 2022;12(1):10-18
doi: https://doi.org/10.14740/jem767

Keywords


DDP4 inhibitors; COVID-19; Diabetes; Systematic review

Full Text: HTML PDF Suppl1
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.